Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (215)

21

T-cell redirecting bispecific antibodies in multiple myeloma : Current landscape and future directions

enthalten in: EJHaem | 2023

von O'Neill, C. | van de Donk, N.

22

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

enthalten in: The New England journal of medicine | 2023

von San-Miguel, J. | Dhakal, B. | Yong, K. | +40

23

T-cell-engaging bispecific antibodies in cancer

enthalten in: Lancet (London, England) | 2023

von van de Donk, N. | Zweegman, S.

24

Management of multiple myeloma-related renal impairment : recommendations from the International Myeloma Working Group

enthalten in: The Lancet. Oncology | 2023

von Dimopoulos, M. | Merlini, G. | Bridoux, F. | +25

25

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity

enthalten in: EBioMedicine | 2023

von Hiemstra, I. | Santegoets, K. | Janmaat, M. | +17

26

Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma

enthalten in: Cancer | 2023

von Martin, T. | Mateos, M. | Nooka, A. | +12

27

Immune Reconstitution and Vaccinations in Multiple Myeloma : A Report From the 19th International Myeloma Society Annual Workshop

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Terpos, E. | Neri, P. | van de Donk, N. | +7

28

Management of patients with multiple myeloma and COVID-19 in the post pandemic era : a consensus paper from the European Myeloma Network (EMN)

enthalten in: Leukemia | 2023

von Terpos, E. | Musto, P. | Engelhardt, M. | +18

29

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma

enthalten in: HemaSphere | 2023

von Verkleij, C. | Frerichs, K. | Broekmans, M. | +24

30

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2023

von Moreau, P. | van de Donk, N. | Delforge, M. | +19